PhenoPath, PLLC

Diagnoses you can count on®

PhenoPath, PLLC is a physician-owned specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.

PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.

PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.

Latest News

  • RAS Launch Notification

    PhenoPath is pleased to announce the launch of extended RAS gene testing. Beginning June 5, 2017, PhenoPath will offer in-house KRAS and NRAS testing that...

    Read More »
  • Phenomena v20.1 (Winter 2017)

    PD-L1 Testing Update, Plasma Based “Liquid Biopsy” Testing for EGFR Mutations, HER2 Clone 4B5, H3K27me3, PhenoPath at USCAP and NCCN, and more!... Read More »

  • Roche cobas® EGFR Plasma Mutation Test

    PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma.

    Read More »

PhenoPath, PLLC

About PhenoPath

Vision

Medical Staff

Executive Staff

Licensing & Accreditation

Careers

Test Menu

Technologies

Diagnostic Services

Clinical Setting

Educational Media

Contact Diagnostic Services

BioPharma Services

Clinical Trial Services

R & D Services

QAU

IT

Contact BioPharma Services

News & Info

Company News

Newsletters

Publications

Upcoming Events

Billing Information

Contact Us

Dept. Inquiries

Submit a Case

Order Supplies

Holidays

Patients & Clients